RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

Shaikamjad Umesalma, … , Frederick W. Quelle, Dawn E. Quelle


Hyperactivated AKT/mTOR signaling is a hallmark of pancreatic neuroendocrine tumors (PNETs). Drugs targeting this pathway are used clinically but tumor resistance invariably develops. A better understanding of factors regulating AKT/mTOR signaling and PNET pathogenesis is needed to improve current therapies. We discovered that RABL6A, a new oncogenic driver of PNET proliferation, is required for AKT activity. Silencing RABL6A caused PNET cell cycle arrest that coincided with selective loss of AKT-S473 (not T308) phosphorylation and AKT/mTOR inactivation. Restoration of AKT phosphorylation rescued the G1 phase block triggered by RABL6A silencing. Mechanistically, loss of AKT-S473 phosphorylation in RABL6A depleted cells resulted from increased protein phosphatase 2A (PP2A) activity. Inhibition of PP2A restored phosphorylation of AKT-S473 in RABL6A depleted cells whereas PP2A reactivation using a specific small molecule activator of PP2A (SMAP) abolished that phosphorylation. Moreover, SMAP treatment effectively killed PNET cells in a RABL6A-dependent manner and suppressed PNET growth in vivo. This work identifies RABL6A as a new inhibitor of the PP2A tumor suppressor and essential activator of AKT in PNET cells. Our findings offer what we believe is a novel strategy of PP2A reactivation for treatment of PNETs as well as other human cancers driven by RABL6A overexpression and PP2A inactivation.

Find the latest version:

http://jci.me/123049/pdf
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

Shaikamjad Umesalma¹, Courtney A. Kaemmer¹, Jordan L. Kohlmeyer², Blake Letney¹, Angela M. Schab¹, Jacqueline A. Reilly¹, Ryan M. Sheehy¹,³, Jussara Hagen¹, Nitija Tiwari¹, Fenghuang Zhan⁴, Mariah R. Leidinger⁵, Thomas M. O’Dorison⁴, Joseph Dillon⁴, Ronald A. Merrill¹, David K. Meyerholz⁵, Abbey L. Perl⁶, Bart J. Brown⁷, Terry A. Braun⁷, Aaron T. Scott⁸, Timothy Ginader⁹, Agshin F. Taghiyev¹⁰, Gideon K. Zamba⁹, James R. Howe⁸, Stefan Strack¹, Andrew M. Bellizzi⁵, Goutham Narla¹¹, Benjamin W. Darbro¹⁰, Frederick W. Quelle¹,⁴, and Dawn E. Quelle¹,²,³,⁵,#

The Department of Pharmacology¹, Molecular Medicine Graduate Program², Free Radical & Radiation Biology Training Program³ and the Departments of Internal Medicine⁴, Pathology⁵, Biomedical Engineering⁷, Surgery⁸, Biostatistics⁹, and Pediatrics¹⁰ in the Colleges of Medicine or Public Health, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. The Department of Pharmacology⁶, Case Western Reserve University, Cleveland, Ohio. The Department of Medicine¹¹, University of Michigan, Ann Arbor, Michigan.

# To whom correspondence and reprint requests should be addressed: Department of Pharmacology, Carver College of Medicine, University of Iowa, 2-570 Bowen Science Bldg., Iowa City, IA 52242. Tel.: 319-353-5749; Fax: 319-335-8930; Email: dawn-quelle@uiowa.edu

Conflict of interest statement: The Icahn School of Medicine on behalf of the author GN has filed patents covering composition of matter on the small molecules disclosed herein for the treatment of human cancer and other diseases and for methods of use for using these small molecule PP2A activators. RAPPTA Therapeutics LLC has licensed this intellectual property for the clinical and commercial development of this series of small molecule PP2A activators. The author GN has an ownership interest in RAPPTA Therapeutics LLC.
Abstract

Hyperactivated AKT/mTOR signaling is a hallmark of pancreatic neuroendocrine tumors (PNETs). Drugs targeting this pathway are used clinically but tumor resistance invariably develops. A better understanding of factors regulating AKT/mTOR signaling and PNET pathogenesis is needed to improve current therapies. We discovered that RABL6A, a new oncogenic driver of PNET proliferation, is required for AKT activity. Silencing RABL6A caused PNET cell cycle arrest that coincided with selective loss of AKT-S473 (not T308) phosphorylation and AKT/mTOR inactivation. Restoration of AKT phosphorylation rescued the G1 phase block triggered by RABL6A silencing. Mechanistically, loss of AKT-S473 phosphorylation in RABL6A depleted cells resulted from increased protein phosphatase 2A (PP2A) activity. Inhibition of PP2A restored phosphorylation of AKT-S473 in RABL6A depleted cells whereas PP2A reactivation using a specific small molecule activator of PP2A (SMAP) abolished that phosphorylation. Moreover, SMAP treatment effectively killed PNET cells in a RABL6A-dependent manner and suppressed PNET growth in vivo. This work identifies RABL6A as a new inhibitor of the PP2A tumor suppressor and essential activator of AKT in PNET cells. Our findings offer what we believe is a novel strategy of PP2A reactivation for treatment of PNETs as well as other human cancers driven by RABL6A overexpression and PP2A inactivation.
Introduction

Neuroendocrine tumors (NETs) are clinically challenging malignancies to manage and treat whose incidence is steadily increasing (1, 2). They are slow growing, biologically diverse tumors that arise from neuroendocrine cells throughout the body (3). NETs in the pancreas (hereafter designated PNETs) are rare, islet-derived neoplasms that nonetheless represent the second most common cancer of the pancreas (4). Most patients with PNETs are asymptomatic or have non-specific symptoms, delaying diagnosis until tumors have advanced and are often metastatic (1, 3, 4). Surgical resection is the first line therapy for primary PNETs, and hepatic cytoreduction may also play a role in the treatment of metastatic tumors (4-6). Somatostatin analogs and peptide receptor radionuclide therapy (PRRT) are important modalities for treating metastatic tumors, as are targeted therapies with the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the receptor tyrosine kinase inhibitor, sunitinib. Chemotherapy is also used for disease control in advanced PNET patients. However, none of these approaches are curative and they have minimal impact on long-term survival, necessitating better therapeutic options for these patients (4, 5, 7-9).

The clinical use of everolimus in patients with advanced PNETs (10-13) was based on evidence that hyperactivation of PI3-kinase (PI3K)/AKT/mTOR signaling is central to PNET progression and associated with worse patient outcomes (14-18). Tumors harbor mutations in pathway genes (e.g., PIK3CA, TSC2 and PTEN) (14, 18) and dysregulation of the proteins is common, including downregulation of the PTEN and TSC2 tumor suppressors and increased phosphorylation of AKT and mTORC1 kinase targets/effectors (S6K, S6 and EIF4EBP1) (15-17). Everolimus therapy significantly increases median progression free survival and, while not statistically significant, is associated with a 6 month improvement in median overall survival (to 44 months) compared with placebo (11, 12). However, sustained inhibition of mTOR with everolimus removes negative feedback control of AKT, paradoxically causing unwanted AKT activation and drug resistance in tumors (19, 20). This has encouraged combination therapies
targeting both mTOR and AKT (10). Given the importance of PI3K/AKT/mTOR signaling in PNET pathogenesis, a greater understanding of factors controlling the pathway is needed to improve current therapies or offer new alternatives, particularly when drug resistance develops.

RABL6A is a novel oncogenic driver of PNETs whose role in cancer cell signaling is beginning to unfold. It is a large, RAB-like GTPase (also called c9orf86, RBEL1 or Parf [Partner of ARF]) that physically and functionally interacts with the Alternative Reading Frame (ARF)-Mdm2-p53 tumor suppressor pathway (21-23). Elevated RABL6A expression is seen in various human cancers, including breast tumors and pancreatic ductal adenocarcinomas where its overexpression is associated with poor survival (24-26). We recently showed that the RABL6A gene is amplified and its protein highly expressed in patient PNETs (23). Moreover, RABL6A is required for PNET cell survival and cell cycle progression, in part through its inactivation of the retinoblastoma (RB1) tumor suppressor (23). It was apparent, however, that additional, currently undefined pathways besides RB1 contribute to and are required for RABL6A-mediated PNET survival and proliferation.

This study sought to identify other clinically relevant pathways regulated by RABL6A in PNETs. We compared gene expression profiles from patient tumors and RABL6A depleted cells and found that RABL6A expression correlated with AKT pathway activation. Analyses of PNET cells showed that RABL6A promotes S473 phosphorylation of AKT, which is required for AKT activation and G1 to S phase progression. RABL6A controls AKT phosphorylation through inhibition of protein phosphatase 2A (PP2A), a powerful tumor suppressor and known regulator of AKT (27-31). Importantly, reactivation of endogenous PP2A with a small molecule activator of PP2A killed PNET cells in a RABL6A-dependent manner and blocked tumor growth in vivo. These discoveries illustrate the biological importance of a novel RABL6A-PP2A-AKT pathway in driving PNET pathogenesis, suggesting new targets (PP2A and RABL6A) for PNET therapy.
Results

RABL6A is required for AKT-mTOR activation in PNETs

We recently showed RABL6A is required for PNET cell proliferation and promotes G1-S phase progression via inactivation of the RB1 tumor suppressor (23). Specifically, PNET cells with RABL6A knockdown failed to proliferate and accumulated hypo-phosphorylated RB1, the growth inhibitory form of the protein. Inactivation of RB1 partially rescued the knockdown phenotype by promoting G1-S phase transition; however, it was unable to override the mitotic block and eventual cell death caused by RABL6A loss. This revealed that RABL6A controls additional pathways besides RB1 to promote PNET cell survival and proliferation (Figure 1A).

To identify other relevant pathways controlled by RABL6A in PNETs, we compared the gene signature of RABL6A expressing PNET cells with that of patient PNETs. Microarray data from BON-1 PNET cells that express or lack RABL6A (23) were used to define the RABL6A signature, while RNA-Seq data from twenty primary human PNETs (compared to normal human pancreas) were examined to identify the most significantly altered genes in patient tumors. The comparison shown in Table 1 revealed remarkable concordance between the two datasets, in keeping with RABL6A amplification (23) and increased mRNA expression (Supplemental Figure 1) in human PNETs. Prominent cancer pathways affected in patient tumors and similarly regulated by RABL6A included p53, RB1, and AKT (Table 1). Having previously examined the importance of p53 and RB1 in RABL6A function in PNETs (23), we focused on the AKT pathway, a major driver of PNET pathogenesis (14-18). Ingenuity Pathway Analysis of the gene expression profiles from RABL6A knockdown (KD) versus control BON-1 cells suggested loss of RABL6A expression impaired AKT pathway activation (Figure 1B).

Activation of AKT requires phosphorylation at two key residues, T308 by phosphoinositide-dependent kinase-1 (PDK1) and S473 by mTORC2 (32, 33). To determine if RABL6A controls AKT activation and signaling, we knocked down endogenous RABL6A in BON-1 cells with two different shRNAs (KD1 or KD2) (23, 26) and assessed AKT
phosphorylation by western blotting. In these cells, RABL6A loss induces an initial cell cycle arrest (mainly in G1 with a moderate G2/M block) that is sustained for 3-5 days followed by apoptosis at later time points (23). Downregulation of RABL6A greatly reduced S473 but not T308 phosphorylation of AKT (Figure 1C). This coincided with a failure of AKT to phosphorylate its substrates, PRAS40 and FoxO1/FoxO3a (Figure 1D), and reduced downstream signaling by mTORC1 kinase as measured by decreased S6K phosphorylation (Figure 1E). Thus, RABL6A is required for AKT-mTOR activation and signaling in PNET cells.

RABL6A promotes G1-S phase progression through AKT activation and sensitizes PNET cells to AKT inhibitors

Given the importance of AKT to tumor cell proliferation and survival (32, 33), we speculated that its inactivation may contribute to the cell proliferation defects caused by RABL6A silencing in PNET cells. To test that idea, we expressed myristoylated AKT (Myr-AKT) in BON-1 cells to determine if constitutively activated AKT could rescue the RABL6A knockdown phenotype. Immunoblotting verified Myr-AKT expression and constitutive phosphorylation at S473, even in RABL6A deficient cells where endogenous AKT-S473 phosphorylation was absent (Figure 2A). Activated Myr-AKT effectively restored phosphorylation of PRAS40-T246 in the RABL6A deficient cells (Figure 2A). BrdU incorporation analyses showed that Myr-AKT promoted a significant increase in DNA synthesis in RABL6A knockdown cells (Figure 2B), although increased AKT activity was not able to restore subsequent cell division in RABL6A depleted cells (see unchanged relative cell numbers, Figure 2A). These results demonstrate that AKT reactivation is sufficient to push cells lacking RABL6A from G1 phase into S phase, identifying a critical role for RABL6A-AKT signaling in PNET cell proliferation (Figure 2C).

The regulation of AKT-mTOR by RABL6A predicts that levels of RABL6A may affect the response of PNET cells to drugs targeting the pathway. Indeed, control BON-1 cells expressing RABL6A were more sensitive to the AKT inhibitor, MK-2206, than RABL6A knockdown cells that
display reduced AKT signaling (Figure 2D). The reduced efficacy of MK-2206 in RABL6A knockdown cells, where AKT is already inhibited, was associated with significantly less drug-induced cell death compared to control cells (Figure 2E). Similarly, RABL6A knockdown cells showed a diminished response to the mTORC1 inhibitor, rapamycin, in cell proliferation assays (Supplemental Figure 2).

**RABL6A regulation of AKT-S473 phosphorylation is independent of mTORC2 and Nek2 kinases**

Phosphorylation of AKT-S473 is mediated by the mTORC2 kinase (34, 35) (Figure 3A). To determine if RABL6A affects mTORC2 kinase formation and activity, we examined endogenous mTORC2 complexes in control and RABL6A knockdown cells by IP-western analyses. Cells were first treated with a cell permeable cross-linking reagent to enable detection of the endogenous complexes (36). No decrease in either the expression or interaction between the essential mTORC2 kinase subunits (mTOR, rictor and GβL) was observed following RABL6A depletion (Supplemental Figure 3). Consistent with that finding, no decrease in the phosphorylation of other mTORC2 substrates, SGK1 and pKCα, was seen in RABL6A knockdown cells (Figures 3B and 3C). In fact, phosphorylation of SGK1 was modestly increased (and PKCα trended similarly) in the same cells where AKT-S473 phosphorylation was dramatically reduced by RABL6A loss (Figure 3C), consistent with evidence that decreased AKT activity can promote mTORC2 activity through a TSC1-TSC2 dependent mechanism (37).

Our data showed that mTORC2 remains active in RABL6A depleted cells, suggesting reduced AKT-S473 phosphorylation may instead be caused by enhanced phosphatase activity.

Dephosphorylation of AKT-S473 has been associated with several different phosphatases including PP1, PP2A and the PH domain leucine-rich repeat protein phosphatases, PHLPP1 and PHLPP2 (27, 38-45) (Figure 3A). PP1 activity toward AKT-S473 is inhibited by NIMA-related expressed kinase 2, Nek2 (46), an oncogenic kinase that we
previously found is downregulated at the mRNA level by RABL6A knockdown (23). Immunoblots verified reduced Nek2 protein expression in RABL6A depleted cells (Supplemental Figure 4A). Therefore, we expressed HA-tagged Nek2 in cells to test if it could override the effects of RABL6A loss on AKT-S473 phosphorylation. High levels of exogenous HA-Nek2 increased basal AKT-S473 phosphorylation in the cells (Supplemental Figure 4B) but failed to restore AKT-S473 phosphorylation in the face of RABL6A loss (Supplemental Figure 4C). Likewise, Nek2 overexpression was unable to stimulate re-entry of RABL6A knockdown cells into the cell cycle, as indicated by the persistently low percentage of cells in S phase. Thus, RABL6A controls AKT-S473 phosphorylation through mechanisms that are independent of mTORC2 and Nek2-PP1.

**RABL6A regulates AKT-S473 phosphorylation through protein phosphatase 2A (PP2A)**

Compared to PP1, the PP2A and PHLPP1/2 (Figure 3A) phosphatases are more strongly linked to AKT dephosphorylation at S473 (38-42). To broadly assess the involvement of phosphatases in RABL6A-mediated AKT regulation, we performed in vitro phosphatase assays using phosphorylated HA-tagged Myr-AKT as substrate. Phospho-Myr-AKT was isolated from HEK 293 cells using HA antibody-coated agarose and incubated with increasing amounts of control or RABL6A knockdown lysates from BON-1 cells. Effects of the lysates on S473 and T308 phosphorylation were measured by western blotting. Relative to control cell lysates that contain normal levels of RABL6A, the RABL6A depleted lysates displayed greater phosphatase activity toward AKT-S473, particularly when 320 μg of lysate was used (Figures 3D and 3E). By comparison, control and RABL6A depleted lysates displayed equal activity toward T308 (Figure 3D), as expected given the specific effects of RABL6A toward S473 phosphorylation.

To test the involvement of PP2A, control and RABL6A knockdown cells were treated with okadaic acid. Okadaic acid is a serine/threonine protein phosphatase inhibitor that specifically blocks PP1 and PP2A activity although it is more potent against the latter,
completely inhibiting PP2A at 1 nM compared to PP1 at 1 µM (47, 48). Notably, PHLPP-mediated dephosphorylation of AKT-S473 is insensitive to okadaic acid (38). In our assays, cells were treated with 100 nM okadaic acid, which yields low nM intracellular concentrations of drug that are selective toward PP2A (49). Western blotting of drug treated cells relative to untreated controls showed that okadaic acid restored a significant amount of AKT S473 phosphorylation in cells lacking RABL6A (Figures 3F and 3G). Moreover, okadaic acid exposure to control cells caused a marked upward shift in endogenous RABL6A mobility on protein gels (Figure 3F, lane 4). These data support two conclusions. First, RABL6A is a likely phosphoprotein and new target (possibly a direct substrate) of PP2A. Second, and more importantly, PP2A is a key downstream target of RABL6A whose activity toward AKT-S473 is normally inhibited by RABL6A.

**PP2A activation reduces AKT-S473 phosphorylation, downregulates RABL6A levels, and induces PNET cell death in a RABL6A dependent manner**

Recent papers published by Dr. Michael Ohlmeyer’s group and us describe specific ‘small molecule activators of PP2A,’ termed SMAPs (50). These tricyclic compounds were originally derived from neuroleptic drugs that were reengineered to neutralize their CNS effects, resulting in a novel class of specific PP2A activating compounds (51, 52). Through extensive testing, SMAPs have shown remarkable efficacy and specificity in stimulating PP2A phosphatase activity toward oncogenic targets (such as phosphorylated ERK1/2) and halting the growth of lung and prostate cancer cells, both in vitro and in vivo, in a PP2A-dependent manner (53-56). We transiently treated parental BON-1 cells, as well as Qgp1 cells (the only other PNET cell line available at the time of this study), overnight with increasing doses of SMAP. SMAP effectively reduced AKT-S473 phosphorylation in both cell lines in a dose-dependent manner with an equivalent effect on ERK1/2 phosphorylation (Figure 4A). This correlated with dramatic reduction in the long-term growth of BON-1 and Qgp1 cells, with
essentially no colonies detected in cells exposed to 10 to 20 μM SMAP (Figures 4B and 4C). Quantitative proliferation assays were conducted to determine the IC50s of SMAP, showing a slightly lower IC50 of ~8 μM in BON-1 cells compared to an IC50 of ~15 μM in Qgp1 cells (Figure 4D). The IC50s for SMAP in PNET cells are similar to those defined for other tumor cell types (53, 54).

To determine if SMAP inhibited PNET cell growth in a RABL6A dependent manner, BON-1 control and RABL6A knockdown cells were treated with increasing doses of SMAP and relative cell numbers quantified. As shown in Figure 4E, loss of RABL6A significantly reduced the cellular response to SMAP treatment. Thus, RABL6A expression sensitizes PNET cells to the effects of PP2A activation by SMAP, demonstrating that SMAP activity in PNET cells is at least partially dependent on RABL6A. Analyses of cell viability, as measured by trypan blue staining in the same populations treated for several days with 10 μM SMAP revealed that RABL6A is required for SMAP-induced cell death (Figure 4F). Notably, western blot analyses of RABL6A in those cells showed that SMAP treatment led to a marked decrease in RABL6A expression, not only in control cells but also RABL6A knockdown cells (Figure 4F, top). While the effect of SMAP on RABL6A expression was less pronounced in experiments involving shorter drug exposure times (as in Figure 4A), the reduction in RABL6A levels caused by SMAP was also associated with loss of slower migrating RABL6A forms on protein gels.

**SMAP effectively suppresses PNET progression in vivo**

Patient derived xenograft (PDX) models for non-functional PNETs are lacking, therefore BON-1 xenograft tumor studies were performed to determine the efficacy of SMAP treatment on PNET tumor progression in vivo. Tumors were grown to approximately 200 mm³ in size, at which time mice were treated by oral gavage with vehicle control, SMAP, the AKT inhibitor MK-2206, or the combination of SMAP plus MK-2206. SMAP treatment caused complete cessation of tumor growth that was superior to single-agent MK-2206 treatment (Figures 5A and 5B).
There was no benefit of combination therapy with SMAP plus MK-2206 (Figures 5A and 5B), in agreement with in vitro drug studies that showed no synergistic effect of their combination (negative data not shown). Treatment with all drugs was well tolerated as indicated by the absence of behavioral abnormalities or changes in body weight during the treatment period (Supplemental Figure 5).

The molecular and biological effects of SMAP treatment were evaluated by western blotting (Figures 5C-F) and immunohistochemical (IHC) staining (Figures 5G and 5H) of the tumors. High synaptophysin expression in the tumors by both approaches verified their NET identity (Figures 5C and 5G). Consistent with the downregulation of endogenous RABL6A expression by SMAP in cultured PNET cells, reduced levels of RABL6A were detected by immunoblotting in the majority of SMAP-treated tumors (Figures 5C-D). Unexpectedly, AKT-S473 phosphorylation in most tumors was increased (not decreased) by treatment with SMAP as well as MK-2206 (Figures 5C, 5E, 5G and 5H). This unwanted effect of SMAP likely reflects loss of negative feedback loops controlling AKT due to sustained exposure to each drug, as seen with everolimus (10, 19, 20).

To determine how SMAP suppressed tumor growth in vivo, expression of apoptotic and proliferation markers was evaluated. No change in cleaved caspase-3 levels was caused by drug treatment (not shown), suggesting SMAP’s anti-tumor effects were unrelated to apoptosis. Interestingly, while there was only a slight (but significant) decrease in the percentage of Ki-67 positive cells in SMAP treated tumors (Figure 5G; 99.6% versus 93.2%, p<0.05, Student’s t test), exposure to SMAP caused a dramatic reduction in Ki-67 levels per cell (Figure 5G). It is known that G1 phase cells express the lowest level of Ki-67 and that residual Ki-67 staining persists in arrested, non-proliferating cells (57, 58). In agreement with that observation, SMAP treatment alone or in combination with MK-2206 significantly decreased RB1-S807/811 phosphorylation (Figures 5C and 5F). Reduced RB1 phosphorylation at those cyclin-dependent kinase (CDK)4/6 specific sites correlates with its activation and G1 phase cell cycle arrest.
Thus, our data suggest that SMAP-mediated PP2A activation effectively halts PNET growth in vivo by inhibiting tumor cell proliferation, likely via a G1 phase blockade that may depend on RABL6A downregulation and RB1 activation.

**Discussion**

This work identifies a RABL6A-PP2A-AKT pathway that drives PNET tumorigenesis, providing new insights into critical upstream regulators that promote aberrant AKT-mTOR signaling in PNETs (Figure 6) and possibly other cancers. We found that RABL6A is a novel inhibitor of PP2A that is required for AKT signaling and G1-S phase progression in PNET cells. RABL6A maintains AKT phosphorylation at S473 by impeding PP2A phosphatase activity. Importantly, an orally bioavailable small molecule activator of PP2A, SMAP, effectively suppressed PNET cell growth in vitro and in vivo. Pharmacological restoration of PP2A tumor suppressive phosphatase activity is an emerging strategy for cancer therapy (29, 30, 50), one that would deliver a new treatment option to clinicians and patients for managing advanced PNETs.

The rationale for reactivating PP2A in anticancer therapy is compelling. First and foremost, PP2A is a powerful tumor suppressor that accounts for over 50% of serine/threonine phosphatase activity in mammalian cells (31, 50). As such, PP2A controls a wide diversity of substrates and exerts its anti-tumorigenic effects by inhibiting numerous oncogenic proteins (such as AKT, Ras, Erk, Myc, JAK2 and STAT5) and activating various tumor suppressor proteins (such as RB1, PTPN6 and GSK-3β) (29, 31, 40). PP2A is inactivated in tumors through various mechanisms including somatic mutation of PP2A subunits, post-translational modifications of the catalytic C subunit, and increased expression of endogenous inhibitors, such as CIP2A and SET (29, 30, 59). Moreover, the transforming activity of certain viral oncoproteins, such as the small T antigen of SV40, depends on their ability to bind PP2A and disrupt its function (59-63). Thus, reactivation of PP2A in tumors using small molecules like
SMAPs should elicit broad-acting anticancer effects with one therapeutic agent, increasing the likelihood that PP2A activation in combination with traditional chemotherapeutics and/or other pathway targeted drugs may eliminate cancers before resistance can develop.

The mechanism(s) by which RABL6A controls PP2A activity is currently not known. The complexity of PP2A itself is immense, with over 80 possible holoenzymes that can be formed from two structural (A) isoforms α and β, two catalytic (C) isoforms α and β, and more than twenty regulatory (B) subunits (31). In PNET cells, altered RABL6A levels had no effect on expression of the A or C subunits of PP2A (Supplemental Figure 6A-C). RABL6A may instead control certain PP2A regulatory B subunits, particularly those (e.g., B56γ and B56β) that regulate AKT-S473 phosphorylation (40-42) and are downregulated in various cancers (29, 30). Among the PP2A inhibitors, increased expression of CIP2A (cancerous inhibitor of PP2A) has been observed in a wide variety of human cancers [reviewed in (29, 30, 50)]. We found that RABL6A loss caused significant downregulation of CIP2A expression (Supplemental Figures 6A and 6D), consistent with elevated PP2A activity in those cells. It is also conceivable that RABL6A regulates PP2A through direct association. A large number of other RAB GTPases (namely RABs 1A, 2A, 8A, 9A, 14, 20 and 31) were recently found by mass spectrometry to interact with PP2A, with analyses of RAB9 showing that it disrupts PP2A holoenzymes via competitive binding to the A subunit (64). RABL6A could impair PP2A assembly and function through a similar mechanism.

Our studies uncovered a negative feedback loop between RABL6A and PP2A (Figure 6). RABL6A expression inhibited PP2A activity toward AKT, while activation of endogenous PP2A with SMAP downregulated RABL6A expression in both cultured PNET cells and tumors. The observation that SMAP activity was diminished in cells lacking RABL6A shows that its anticancer effects depend, in part, on inhibition of RABL6A. It remains to be determined if PP2A directly regulates RABL6A. Selective manipulation of PP2A activity with either okadaic acid (inhibitor) or SMAP (activator) had reciprocal effects on the migration of RABL6A on denaturing
protein gels. We suspect those effects on RABL6A migration reflect altered phosphorylation and that dephosphorylated RABL6A is unstable. According to phosphorylation site databases, RABL6A is phosphorylated at numerous sites (Supplemental Table 1). Ongoing studies will test the possibility that PP2A antagonizes RABL6A activity by dephosphorylating and destabilizing the protein, thereby reducing RABL6A expression.

It is likely that RABL6A influences the activity of other cellular phosphatases since AKT-S473 phosphorylation levels were only partly restored by okadaic acid-mediated inhibition of PP2A. Two isoforms of the PHLPP phosphatase exist and inactivate different AKT isoforms through direct binding and dephosphorylation of S473 (39). While PHLPP1 acts on AKT2 and AKT3, PHLPP2 regulates S473 phosphorylation and activity of AKT1 and AKT3 (39). It will be important to determine which isoform(s) of AKT is affected by RABL6A and if PHLPP isoforms contribute to that regulation, particularly since PHLPP1 and PHLPP2 are tumor suppressors whose genetic deletion in certain cancers, such as prostate cancer, rivals that of another tumor suppressive phosphatase, PTEN (65).

This study suggests that drugs targeting RABL6A or PP2A could provide beneficial new therapies for PNET patients. There are currently no known inhibitors of RABL6A. SMAPs are attractive therapeutics since pre-clinical studies show they are well-tolerated oral drugs with significant in vivo activity toward PNETs (this study) as well as Ras-driven lung cancer and prostate adenocarcinoma (53, 54). Other PP2A activating drugs function as indirect activators of PP2A by targeting PP2A’s endogenous inhibitors and typically have non-PP2A related activity. One example, FTY720 (fingolimod), is an FDA-approved drug for multiple sclerosis increases PP2A activity through SET inhibition but also has immunosuppressive activities that may be undesirable for cancer patients (29, 30). As such, non-immunosuppressive derivatives of FTY720 ([S]-FTY720-OMe, [S]-FTY720-regioisomer, and OSU-2S) may hold more promise as anti-cancer agents. Indeed, OSU-2S displayed potent anti-tumor activity in pre-clinical in vitro
and in vivo studies against various hematologic malignancies and hepatocellular carcinoma (66-68).

As we look to improve and expand treatment options for patients with advanced PNETs, one significant clinical consideration is our finding that sustained reactivation of PP2A in tumors caused an unwanted increase in AKT activation. A similar effect is observed with prolonged everolimus therapy due to loss of negative feedback control and induction of tyrosine kinase receptor signaling (10, 19, 20). It is therefore encouraging that the PNETs still responded well to SMAP treatment (complete stoppage of tumor growth), implying that other cancer pathways regulated by PP2A override the oncogenic effects of AKT. One of those other pathways may be ERK signaling; it is promoted by RABL6A (26, 69), was inhibited in SMAP treated PNETs (Figure 5C), and contributes to SMAP’s anti-cancer effects in Ras-driven tumors (53). As shown in Figure 6, PP2A also promotes RB1 tumor suppressive activity through dephosphorylation of RB1 (70) and dephosphorylation / stabilization of the CDK inhibitor, p27 (71, 72). We previously showed RB1 is inhibited by RABL6A in PNETs (23), and here found that PP2A reactivation in tumors caused marked RABL6A loss and RB1 activation. Additional studies will be needed to define the relative importance of RABL6A downregulation and/or RB1 activation in mediating the anti-tumor effects of SMAP, and to determine the degree to which RB1 hypophosphorylation depends on PP2A-induced RABL6A loss versus PP2A activation.

In summary, PP2A reactivation and RABL6A inhibition may be promising strategies for PNET treatment. The fact that RABL6A expression dictated PNET cell response to drugs targeting AKT, mTOR and PP2A also suggests that tumor levels of RABL6A may be a predictive biomarker for therapies against each of those pathways. More research in patient NETs, a newly developed PNET cell line (73), and other types of NETs, such as bronchial NETs for which cell lines are available, will establish how generalizable aberrant RABL6A-PP2A-AKT signaling is to NET pathogenesis and if pathway status predicts tumor responsiveness to targeted therapies.
**Materials and Methods**

**Cell culture and reagents.** Two human PNET cell lines have been established and are available, and both were used for these studies. BON-1 cells (originally developed from a lymph node metastasis of a PNET and authenticated by Dr. Courtney Townsend, University of Texas Medical Branch, Galveston, TX) (74) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) / F12 containing 10% fetal bovine serum (FBS), 4 mM glutamine, and 100 μg/mL penicillin-streptomycin. Qgp1 cells were purchased from the Japanese Collection of Research Bioresources (JCRB0183) and maintained in RPMI 1640 medium containing 10% FBS, 4 mM glutamine, and 100 μg/mL penicillin-streptomycin. RABL6A gene and protein expression in BON-1 and Qgp1 cells relative to non-transformed controls is not known since NET control cell lines are lacking. However, karyotype and qPCR analyses suggest there are additional copies of the *RABL6* gene in both PNET cell lines (Supplemental Figure 7). Moreover, both cell lines express elevated levels of RABL6A protein similar to primary PNET and small bowel NET cultures derived from patient tumors (Supplemental Figure 8). Human embryonic kidney (HEK) 293T cells were grown in DMEM with the same supplements listed above. Cells were routinely tested for mycoplasma contamination and found to be negative.

Cells were treated with the indicated concentrations of okadaic acid (PP2A inhibitor, Cell Signaling [5934], dissolved in DMSO and stored at -20°C), MK-2206 (AKT inhibitor, Selleck Chemicals, reconstituted in DMSO and stored at -20°C) or SMAP compound (PP2A activator, dissolved in DMSO and stored at room temperature, provided by Dr. Goutham Narla, The University of Michigan, Ann Arbor, MI).

**RNA interference, virus production and infection.** Human RABL6A shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL) have been described (23, 26). Lentiviruses encoding RABL6A shRNAs were produced in HEK 293T cells and infected into target cells (BON-1, Qgp-1), as described (23, 26). Cells were harvested 3 to 5 days after
infection depending on the assay. For combined overexpression of HA-tagged myristoylated AKT (HA-Myr.AKT) and silencing of RABL6A, cells were sequentially infected with pMSCV-HA-Myr.AKT-IRESGFP viruses followed by RABL6A shRNA or CON viruses. Lentiviruses co-expressing HA-tagged Nek2 kinase and GFP were similarly produced in HEK 293T cells and infected into BON-1 cells, and GFP-positive cells selected by sterile cell sorting (FACS Aria II, Becton Dickinson). Cells infected with RABL6A shRNA viruses were selected with 1 µg/mL puromycin for 2 days and maintained in 0.5 µg/mL puromycin for the remainder of the assay.

**Cell proliferation and survival assays.** Cell number and viability were directly measured by trypan blue staining (1:1 v/v) and manual counting using a hemocytometer following infection with RABL6A shRNA viruses and/or treatment with drugs. Where indicated, relative cell numbers were quantified using alamarBlue® (ThermoFisher Scientific) or Cell-Quant™ (Genecopoeia) assays in a 96-well format according to manufacturer’s instructions. To measure DNA synthesis, infected cells were plated onto coverslips and the next day incubated with 10 µM bromodeoxyuridine (BrdU) for 5 hrs. BrdU incorporation was detected by immunofluorescent staining with anti-BrdU antibodies and 4',6-diamidino-2-phenylindole (DAPI) to detect nuclei (75). Confocal microscopy (Zeiss LSM 710, Germany) was performed to capture fluorescence images and quantify BrdU positivity (100 or more cells per sample counted) from 3 or more separate experiments.

**RNA expression analyses.** Microarray analysis of total RNA from 3 separately generated sets of BON-1 cells expressing RABL6A shRNAs or control vector has been described (23). Differentially expressed genes between the RABL6A knockdowns and vector were analyzed by Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, Redwood City, CA). Significant gene set enrichment was defined as reaching a P value less than 0.01 after a Benjamini-Hochberg multiple testing correction. The “Upstream Analysis” component of
the IPA Core Analysis was used to specifically assess for enrichment of genes involved in AKT pathways.

RNA-Seq analysis of human PNET specimens was performed on primary tumors collected from 20 patients during operative procedures at the University of Iowa Hospitals and Clinics. RNA was isolated from tissues stored in RNAlater (ThermoFisher Scientific) using the RNeasy Plus kit (Qiagen), subjected to DNA digestion and resuspended in water prior to RNA quality assessment using the Agilent 2100 Bioanalyzer (Agilent Technologies). Samples with an RNA integrity number (RIN) > 6 were sequenced using the Illumina TruSeq protocol (Illumina, Inc) at the University of Iowa Institute of Human Genetics Genomics Division, exactly as described (76). RNA-Seq reads were mapped with the STAR aligner (77). StringTie was used for assignment of reads to transcripts, quantification of expression and normalization (78). BallGown was used to determine differential gene expression (79). RNA-Seq data will be deposited in the NCBI dbGaP database (accession no. phs001772.v1.p1, web address https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001772.v1.p1). Statistically significant gene expression changes were indicated by an adjusted $P$ value less than 0.05.

**Antibodies.** For western blotting, antibodies specific for AKT (no. 4691), p-AKT-S473 (no. 4060), p-AKT-T308 (no. 9275), ERK (no. 4695), p-ERK-T202/Y204 (no. 9106), PRAS40 (no. 2997), p-PRAS40-T246 (no. 2610), p70 S6 Kinase (no. 2708), p-p70 S6 Kinase-T389 (no. 9206), PKCα (no. 2056), cleaved caspase-3 (no. 9661), mTOR (no. 2983), rictor (no. 9476), GβL (no. 3274), p-RB1-S807/S811 (no. 9308S), RB1 (no. 9309S), PP2A A subunit (no. 2041), and p-FoxO1-T24/p-FoxO3a-T32 (no. 9464) were obtained from Cell Signaling Technology. An SGK1 antibody was obtained from Millipore (no. 07-315). GAPDH (no. Ab8245), Synaptophysin (no. Ab32127) and PP2A C subunit (no. Ab106262) antibodies were purchased from Abcam. Vinculin (no. V9131) and HRP-coupled secondary antibodies (nos. NA931, NA934 and NA935) were obtained from Sigma. The 3F10 rat monoclonal antibody to HA (no. 11867423001) was
obtained from Roche. Antibodies to p-SGK1-S422 (no.SC-16745), p-PKCα-S657 (no. SC-12356), Nek2 (no. SC-55601) and CIP2A (no. SC-80659) were purchased from Santa Cruz. A rabbit polyclonal antibody to RABL6A was produced in the Quelle laboratory (21). For immunohistochemistry, antibodies to p-AKT-S473 (no. 4060, Cell Signaling Technology), synaptophysin (DAK-SYAP clone, Dako-Agilent), Ki-67 (no. 16667, Abcam), and RABL6A (monoclonal generated in the Quelle laboratory, (26)) were used.

**Western blotting.** Cellular proteins were isolated from cells by lysis in SDS-PAGE loading buffer and identical cell equivalents electrophoresed through polyacrylamide gels. Whole cell extracts and tumors were lysed for 30 min on ice with RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate) supplemented with 1 mM NaF, protease and phosphatase inhibitor cocktails (Sigma, P-8340 & P-0044) and 30 µM phenylmethylsulfonyl fluoride (PMSF). Protein concentrations of cell extracts were determined by Precision Red protein assay reagent (Cytoskeleton, ADV02) and equal quantities of protein were loaded for separation of proteins. Proteins were transferred onto PVDF membranes (Millipore), which were blocked with 5% nonfat milk or 3% BSA in TBST (Tris-buffered saline containing Tween-20) depending on the antibody used for protein detection. Western blotting conditions for primary antibodies can be found in **Supplemental Table 2.** After incubation with primary antibodies, membranes were washed in TBST and incubated for 40 min at room temperature with HRP-conjugated secondary antibodies. Proteins were visualized with enhanced chemiluminescence (ECL, Amersham, Buckinghamshire, UK), as described (80). Densitometry quantification was performed using ImageJ (NIH) software.

**Analysis of mTORC2 kinase complexes.** To detect endogenous cellular mTORC2 complexes, BON-1 cells expressing control or RABL6A shRNAs were washed in phosphate buffered saline (PBS) and incubated with 1.25 mM DSP (dithiobis[succinimidylpropionate], ThermoScientific, #22586, suspended in DMSO at 25 mM and diluted in PBS), a cell permeable cross-linking reagent for 30 min at room temperature (RT). The cross-linking reaction was
halted by incubation with 20 mM Tris, pH 7.6, for 15 min at RT. Cells were rinsed in PBS and lysed directly in ice-cold NP-40 buffer (50 mM Tris, pH 8.0, 120 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, and 0.1 mM Na3VO4) supplemented with 1 mM NaF, protease inhibitor cocktail (Sigma Aldrich, P8340) and phosphatase inhibitor cocktail (Sigma Aldrich, P0044). Samples were sonicated for 5 sec and lysates clarified by centrifugation at 15,000 rpm for 10 min at 4°C. mTORC2 complexes were immunoprecipitated by overnight incubation at 4°C using Rictor antibodies (Cell Signaling, 9476) and protein A/G-Sepharose versus an isotype-matched IgG control. Immune complexes were washed 4 times in NP-40 buffer, separated by SDS-PAGE, transferred to PVDF membranes, and analyzed by immunoblotting (see Supplemental Table 2 for antibodies).

In vitro phosphatase assay. An in vitro phosphatase assay was performed using phosphorylated HA-Myr-AKT as the substrate. HEK 293T cells expressing HA-tagged Myr-AKT were lysed in RIPA buffer lacking phosphatase inhibitors and the protein purified by binding to anti-HA affinity matrix (Sigma-Aldrich) at 4°C overnight. The resin was washed 3 times in ice-cold RIPA buffer, 2 times in ice-cold, hypotonic phosphatase reaction buffer (50 mM Tris, pH 7.5, 10 mM MgCl2, 20 mM dithiothreitol, 5 mM EDTA), and finally resuspended in phosphatase reaction buffer containing 30% glycerol and stored at 4°C. BON-1 cells expressing CON or RABL6A shRNA constructs were harvested, washed once in PBS, suspended in phosphatase reaction buffer containing protease inhibitors (protease inhibitor cocktail [Sigma, P8340] and 30 µM phenylmethylsulfonyl fluoride) for 10 min on ice, and briefly sonicated (1 x 5 sec pulse). Lysates were clarified by centrifugation at 15,000 rpm for 5 min at 4°C, and protein concentrations determined by Precision Red (Cytoskeleton, ADV02). Varying amounts of each cell lysate were incubated with 5 µl (1:1 slurry) of purified HA-Myr-AKT substrate for 20 min at 30°C, with all reaction volumes made equivalent by addition of buffer. As negative controls, an equivalent volume of buffer (no lysate) was added to the substrate or 50 mM KF (phosphatase inhibitor) was added to the cell lysate prior to performing the phosphatase reaction. Reactions
were stopped by the addition of SDS-PAGE buffer and boiling for 10 min. Phosphatase activity within each lysate was measured by western blotting for levels of phosphorylated AKT-S473 and AKT-T308 relative to total levels of HA-Myr-AKT (using HA antibodies) in each reaction.

**Drug response assays.** Chemotherapeutic drugs MK-2206 (AKT inhibitor) and Rapamycin (mTORC1 inhibitor) were purchased from Selleck Chemicals (Houston, TX, USA) and stocks stored at -20°C once in solution. Rapamycin was dissolved in sterile ddH₂O whereas MK-2206 and SMAP were dissolved in dimethyl sulfoxide (DMSO). SMAP solution was stored at RT and used for up to 1 month. BON-1 and Qgp1 cells were seeded at a density of 2,000 cells per well in 96-well flat-bottomed culture dishes. After overnight incubation, an equal volume of 2X concentrated drug was added to each well and cells exposed to the drugs for three to five days. Each condition was performed in triplicate. Samples were assayed for relative cell number using alamarBlue® (Thermo Fisher Scientific, DAL1025) or Cell-Quant™ (GeneCopoeia, A014) cell proliferation assays. Results were quantified using a fluorescence microplate reader by measuring absorbance at wavelengths of 540/570nm for alamarBlue® and 480/530nm for Cell-Quant™.

To measure effects of MK-2206, SMAP and okadaic acid on RABL6A levels and AKT-S473 phosphorylation, cells plated in 6-well dishes were treated with vehicle control or the indicated drug concentrations for 16-20 hours at 37°C, 5% CO₂. Cells were harvested, lysed in RIPA buffer and subjected to western blotting. In some assays, cells were exposed for longer periods of time (up to 3 days) to the drugs, and cells examined by trypan blue staining to assess cell viability and by western blotting to evaluate protein status.

**Clonogenic assay.** Cells were plated at low density (250, 500 and 1000 cells per well) in 6-well plates. After 24 hours, cells were treated in triplicate with vehicle control or increasing concentrations of SMAP and incubated for 3 weeks. Drug-containing medium was refreshed every 72 hrs. Cells were then fixed and stained with 1% crystal violet solution (Sigma-Aldrich). Quantification was performed using a GelCount™ colony counter (Oxford Optronix Ltd).
Mouse tumor xenografts and treatment studies. Mice were housed in the University of Iowa Animal Care barrier facility in rooms with a 12-hour light-dark cycle and free access to water and food. For tumor studies, the right flanks of eight-week-old immunodeficient female mice (homozygous NOD.CB17-Prkdc<sup>Scid</sup>/J strain, model 001303, Jackson Laboratory) were injected subcutaneously with BON-1 cells (5 × 10<sup>6</sup>) suspended in 0.2 ml of 1:1 PBS/Matrix gel (BD Biosciences). When tumor volumes reached an average of 200 mm<sup>3</sup>, mice were randomized into the different treatment groups and tumor volume was assessed by caliper measurement two times a week throughout the study. Tumor volume was determined using the formula: [width(2) × length]/2. Mice were treated by oral gavage with vehicle control, MK-2206 (30mg/kg, 3 times per week), SMAP (5 mg/kg, twice daily), and SMAP plus MK-2206. Mouse body weights were recorded 2 times per week. SMAP was prepared in a N,N-Dimethylacetamide (DMA) / Kolliphor HS-15 (Solutol) /dH<sub>2</sub>O solution. Animals were observed for signs of toxicity (weight loss, ruffled fur, immobility and abdominal rigidity). Tumor tissues, harvested 2 hours post-final dose of treatment, were weighed and split for processing by fixation in 10% neutral buffered formalin (for IHC analyses) or flash frozen in LN2 (for western blotting).

Histopathological analysis. Formalin (10% neutral buffered formalin) fixed tumors were routinely processed, paraffin embedded, and sectioned (~4 µm) onto glass slides. Slides were stained with hematoxylin and eosin (H&E) (81) and reviewed by a pathologist (Dr. Bellizzi). For immunostaining of phosphorylated AKT-S473 (Cell Signaling Technology, antibody #4060) and Ki-67 (Abcam, antibody #16667), we used Dako Rabbit Envision (Dako-Agilent) and chromogen was DAB with Harris hematoxylin counterstain. The synaptophysin immunostain was run on a Dako Autostainer Link 48 after HpH antigen retrieval using a mouse monoclonal antibody (DAK-SYNAP clone from Dako-Agilent; 1:100; 15-minute incubation) followed by detection using the polymer-based EnVision FLEX+ detection system. Synaptophysin and phosphorylated AKT-S473 were scored as weak = 1, moderate = 2, or strong = 3. Ki-67 was
quantified by the number of positively stained cells (regardless of staining intensity) in
approximately 500 tumor cells per tumor sample.

**Statistics.** Western blot data were imaged by scanning densitometry and quantified by
ImageJ software (NIH). Values for phosphoproteins were normalized to expression of the total
protein while values for all other proteins were normalized to the loading control. Differences in
levels of protein phosphorylation or expression were expressed as fold change relative to
untreated counterparts or vector controls. Quantified data were presented as the mean +/- SD
or SEM, as indicated. All P values, unless otherwise specified, were obtained by two-way
ANOVA and adjusted for multiple comparisons using the Bonferroni method. Overall differences
between curves were assessed using generalized linear regressions. An adjusted P value less
than 0.05 was considered statistically significant.

**Study approval.** All patients were consented for genetic studies and entered into a
Neuroendocrine tumor registry approved by the University of Iowa Hospitals and Clinics
institutional review board (IRB # 199911057). All mouse studies were conducted according to
protocols approved by the University of Iowa Institutional Animal Care and Use Committee
(protocol # 5121590: molecular mechanisms and biomarkers of neuroendocrine tumors). All
efforts were made to minimize animal suffering.
Author contributions
SU, GN, BWD, FWQ and DEQ conceived and designed the studies. SU, CAK, JLK, BL, JAR, AMS, RMS, JH, NT, MRL, TAB, BJB, ATS, TG, AFT, GZ, AMB, BWD and DEQ conducted experiments and analyzed the data. FZ, TMO, JD, JRH, DKM, ALP, RM, AMB, SS, GN, BWD, FWQ and DEQ provided observations and scientific interpretations. All authors reviewed, discussed and approved of the manuscript.

Acknowledgements
We thank Dr. David Gordon for advice on combination drug therapies and are grateful for assistance from personnel in the core facilities within the University of Iowa College of Medicine and Holden Comprehensive Cancer Center (Flow Cytometry, Central Microscopy and Genomics Core). We especially thank the Iowa NET SPORE group for critical feedback as this work was being conducted and the Iowa NET Registry Database (which is housed within the CTSA RED CAP). This work was supported by grants from the NIH including NCI Neuroendocrine Tumor SPORE grant P50 CA174521 [Project 2, DEQ and BWD; Project 3, JRH, AB and TB; Developmental Research Project, DEQ and JRH], 2T32 GM0677954 [JK], 5T32 CA078586 [RMS], and an NCI Core Grant P30 CA086862 [University of Iowa Holden Comprehensive Cancer Center].
References


Figure 1. RABL6A depletion impairs AKT-S473 phosphorylation and AKT-mTOR signaling in PNETs. (A) Schematic showing that RABL6A promotes PNET cell proliferation and survival through multiple mechanisms, including inhibition of RB1 signaling as well as regulation of other undefined (X, Y) pathways. Arrow, activating event; perpendicular bar, inhibitory event. (B) BON-1 cells expressing vector control (CON, + RABL6A) or shRNAs targeting RABL6A (KD1 and KD2, – RABL6A) were examined by microarray analyses. Heat map shows RABL6A depletion significantly alters the expression of genes involved in AKT signaling; data from 3 experiments, designated A-C. Genes were categorized by IPA software and displayed 2-fold or greater changes in expression (P < 0.05). Red, relatively increased expression; blue, relatively decreased expression. (C) Representative western blots showing that RABL6A knockdown (KD1, KD2) in BON-1 cells specifically reduces the activating phosphorylation of AKT at S473, not T308. Vinculin served as loading control. Relative phosphorylation of each residue relative to total AKT was quantified by ImageJ. (D) Representative western blots showing that inactivation of AKT in RABL6A knockdown BON-1 cells coincides with reduced phosphorylation of AKT substrates, PRAS40-T246 and FoxO1-T24/FoxO3a-T32, with GAPDH as loading control. (E) Representative western blots showing that inactivation of AKT in RABL6A knockdown BON-1 cells coincides with reduced activation of mTORC1, as measured by decreased S6K phosphorylation at T389. GAPDH was the loading control. S6K-T389 phosphorylation relative to total S6K was quantified by ImageJ. Experiments in C-E represent at least 3 independent experimental repeats.
Figure 2. RABL6A-AKT signaling is required for PNET cell cycle progression and response to AKT inhibitors. (A) BON-1 cells expressing vector (Vec) or constitutively activated myristoylated AKT (Myr-AKT) were infected with control (CON) or RABL6A shRNAs (KD1, KD2). Representative western blots of phosphorylated AKT-S473 detect endogenous AKT (bar, lower band) and Myr-AKT (arrow, upper band only in lanes 4-6). Heightened activity of Myr-AKT was assessed by levels of PRAS40-T246 phosphorylation. β-actin served as the loading control. Cell ratios (i.e., relative cell numbers normalized to CON cells) are indicated for each sample. (B) The percentage of BrdU-positive cells was quantified in BON-1 control and RABL6A knockdown cells expressing vector (V) versus Myr-AKT (M). Data were quantified from 3 independent experiments; *, P < 0.02 for V versus M comparison, two-way ANOVA. (C) Schematic of RABL6A promoting G1-S phase progression and PNET cell proliferation by activating AKT signaling. (D) Dose response curves, shown as relative cell number, in BON-1 control and RABL6A knockdown cells treated for five days with increasing concentrations of the AKT inhibitor, MK-2206. Data represent the mean +/- SEM for triplicate samples from three separate experiments. *, P < 0.001 for KD1 or KD2 compared to CON, two-way ANOVA and adjusted for multiple comparisons using the Bonferroni method. Overall differences between the curves were assessed by generalized linear regressions. (E) Percent cell death in BON-1 control and RABL6A knockdown cells following treatment with MK-2206 (10 μM) for three days. Data represent the mean +/- SEM from 3 independent experiments, in which results were normalized to values for untreated cells within each group. *, P < 0.001 for (+) versus (-) comparison, two-way ANOVA and adjusted for multiple comparisons using the Bonferroni method.
Figure 3. RABL6A increases AKT-S473 phosphorylation through inhibition of PP2A.

(A) Schematic of the kinases and phosphatases that regulate AKT-S473 phosphorylation. P, phosphorylation; arrows, activating events; perpendicular bars, inhibiting events. (B) Westerns of BON-1 control (CON) and RABL6A knockdown (KD1 and KD2) cells showing selective loss of pAKT-S473 in RABL6A depleted cells versus moderately increased phosphorylation of other mTORC2 substrates, SGK1 and PKCα. GAPDH was the loading control. (C) Relative phosphorylation of mTORC2 substrates in BON-1 CON, KD1 and KD2 cells was quantified by ImageJ. Data represent the mean +/- SD from three independent experiments (*, P < 0.05 and **, P < 0.001 compared to CON, two-way ANOVA and adjusted for multiple comparisons using the Bonferroni method). (D) Western blots of pAKT-S473 and pAKT-T308 following in vitro phosphatase assays using phosphorylated HA-tagged Myr-AKT as substrate to which the indicated amounts (μg) of BON-1 CON, KD1 or KD2 lysates were added. As controls, buffer (-) or the general phosphatase inhibitor, potassium fluoride (KF), was added to substrate prior to the phosphatase reaction. (E) Relative levels of pAKT-S473, normalized to total HA-Myr-Akt, were quantified by ImageJ analysis of blots from 3 or more experiments in which 320 μg of cell lysate was tested. *, P < 0.005 KD (KD1 and KD2) versus CON, two-way ANOVA adjusted for multiple comparisons using the Bonferroni test. (F) Westerns of pAKT-S473, AKT and RABL6A following okadaic acid (OA) treatment (100 nM, 20 hrs) in BON-1 CON and KD cells showing significant restoration of pAKT-S473 by PP2A inhibition. Vinculin was loading control. (G) Relative phosphorylation of AKT-S473 was quantified from 3 experiments. **, P < 0.005 compared to untreated counterparts, two-way ANOVA adjusted for multiple comparisons using the Bonferroni method. Westerns in B, D and F are representative of 3 or more experiments.
Figure 4. PP2A reactivation with SMAP reduces AKT-S473 phosphorylation, downregulates RABL6A, and induces PNET cell death in a RABL6A-dependent manner. (A) Western blots (repeated 3 or more times) of lysates from BON-1 and Qgp1 cells treated 20 hrs with SMAP showing effective reduction of pAKT-S473 and pERK-T202/Y204. Loading, vinculin (BON-1) and GAPDH (Qgp1). (B) Representative images from clonogenic assays of BON-1 and Qgp1 cells treated with 0 (vehicle), 5, 10 or 20 µM SMAP for 3 weeks. (C) Quantification of clonogenic assay results, normalized to 100% for vehicle treated control cells, from two separate experiments performed in triplicate. *, P < 0.001, two-way ANOVA and adjusted for multiple comparisons using the Bonferroni method. Identical results were obtained in 4 additional repeats per cell line for cells plated at different densities. (D) Representative experiment (repeated twice) showing dose response curves for BON-1 and Qgp1 cells following exposure for 3 days to indicated concentrations of SMAP. Data represent the mean +/- SD for triplicate samples and were normalized to values from untreated cells. (E) Relative cell number (assayed by Cell-QuantTM) of BON-1 cells expressing CON, KD1 or KD2 shRNAs after exposure for 3 days to increasing concentrations of SMAP. Data (from 3 experiments done in triplicate) were normalized to untreated controls. *, P < 0.001 for KD1 and KD2 compared to CON, two-way ANOVA and adjusted for multiple comparisons using the Bonferroni method. Overall differences between curves were assessed using generalized linear regression. (F) BON-1 CON, KD1 and KD2 cells were treated with 10 µM SMAP for 3 days. Dark and light exposures of westerns show PP2A activation decreased RABL6A levels and altered its migration on gels. *, P < 0.05 for untreated versus treated samples, Student’s t test. Error bars in panels E-F, SEM for data from 3 independent experiments.
Figure 5. Therapeutic reactivation of PP2A suppresses PNET growth in vivo. (A) BON-1 cells ($5 \times 10^6$) were injected subcutaneously into NOD.SCID mice. Once tumors reached an average volume of 200 mm$^3$, drug treatments were initiated. Tumor volumes were measured over a 4-week period in which mice were treated by oral gavage with vehicle control, SMAP 5 mg/kg (twice a day), MK-2206 30 mg/kg (three times a week) and a combination of SMAP plus MK-2206. SEM for at least n=5 mice per group; *, $P < 0.03$ for vehicle versus SMAP or SMAP+MK-2206; #, $P < 0.05$ for vehicle versus MK-2206; two-way ANOVA and adjusted for multiple comparisons using Bonferroni method. (B) Comparison of tumor weights from vehicle (V), SMAP (S), MK-2206 (M) and SMAP+MK-2206 (S+M) groups after the final treatment. Error bars, SEM: *, $P < 0.001$, two-way ANOVA and adjusted for multiple comparisons using the Bonferroni method. (C) Representative western analyses of the indicated proteins in lysates of xenografted BON-1 tumors harvested from the treated mice. (D), (E) and (F) Quantification of relative levels of RABL6A, pAKT-S473, and pRB1-S807/811 in xenograft tumors, respectively, obtained by ImageJ analysis of western blots (as shown in (C)). Mean +/- SEM; *, $P < 0.05$; **, $P < 0.01$; two-way ANOVA and adjusted for multiple comparisons using the Bonferroni method. (G) Representative H&E and IHC staining for the indicated proteins in BON-1 xenograft tumors from vehicle control and SMAP treated mice. Images were taken at 400X. (H) Quantification of pAKT-S473 staining (assessed as weak = 1, moderate = 2, strong = 3) in tumors from vehicle (V) and SMAP (S) treated mice. Mean +/- SEM; *, $P < 0.001$, Student’s t test.
Figure 6. RABL6A oncogenic signaling in PNETs. Schematic showing that RABL6A inhibits the PP2A tumor suppressor, thereby activating AKT-mTOR signaling to drive PNET proliferation and survival. In turn, PP2A can inhibit expression of RABL6A, possibly via dephosphorylation and destabilization of the protein. Earlier work showed that RABL6A can promote PNET pathogenesis by inhibiting RB1, which was associated with downregulation of CDK inhibitors (p21 and p27) and increased RB1 phosphorylation (23). PP2A-mediated dephosphorylation of p27 and RB1 increases their activities, representing additional mechanisms by which PP2A may antagonize RABL6A. Although not shown, AKT also inhibits RB1 signaling through several mechanisms. The pathways depicted here, as well as drug response assays performed in this study, predict that high RABL6A expression in patient PNETs will sensitize tumors to clinically relevant drugs that inhibit CDKs (Palbociclib), activate PP2A (SMAP), inhibit AKT (MK-2206), and inhibit mTORC1 (Everolimus). Arrows, activating events. Perpendicular bars, inhibitory events.
Table 1. Comparison of RABL6A regulated genes with significantly altered genes in human PNETs.

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Gene description</th>
<th>RABL6A regulation</th>
<th>Patient PNET regulation</th>
<th>Key cancer pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABAT</td>
<td>4-aminobutyrate aminotransferase</td>
<td>Down</td>
<td>-2.815</td>
<td>2.46E-02</td>
</tr>
<tr>
<td>BTG2</td>
<td>BTG anti-proliferation factor 2</td>
<td>Down</td>
<td>-14.088</td>
<td>5.31E-15</td>
</tr>
<tr>
<td>BUB1</td>
<td>BUB1 mitotic checkpoint serine/threonine kinase</td>
<td>Up</td>
<td>26.282</td>
<td>2.01E-07</td>
</tr>
<tr>
<td>BUB1B</td>
<td>BUB1 mitotic checkpoint serine/threonine kinase B</td>
<td>Up</td>
<td>12.47</td>
<td>9.24E-07</td>
</tr>
<tr>
<td>CCNA2</td>
<td>Cyclin A2</td>
<td>Up</td>
<td>8.539</td>
<td>2.14E-06</td>
</tr>
<tr>
<td>CCNB1</td>
<td>Cyclin B1</td>
<td>Up</td>
<td>3.901</td>
<td>6.26E-06</td>
</tr>
<tr>
<td>CENPF</td>
<td>Centromere protein F</td>
<td>Up</td>
<td>37.172</td>
<td>1.33E-08</td>
</tr>
<tr>
<td>ELF4</td>
<td>E74 like ETS transcription factor 4</td>
<td>Up</td>
<td>3.65</td>
<td>1.52E-04</td>
</tr>
<tr>
<td>FEN1</td>
<td>Flap structure-specific endonuclease 1</td>
<td>Up</td>
<td>2.167</td>
<td>4.70E-03</td>
</tr>
<tr>
<td>KIF23</td>
<td>Kinesin family member 23</td>
<td>Up</td>
<td>5.577</td>
<td>2.55E-04</td>
</tr>
<tr>
<td>MAD2L1</td>
<td>MAD2 mitotic arrest deficient-like 1 (yeast)</td>
<td>Up</td>
<td>7.279</td>
<td>3.17E-07</td>
</tr>
<tr>
<td>MCM2</td>
<td>Minichromosome maintenance complex component 2</td>
<td>Up</td>
<td>2.542</td>
<td>9.88E-03</td>
</tr>
<tr>
<td>MYC</td>
<td>v-myc avian myelocytomatosis viral oncogene homolog</td>
<td>Up</td>
<td>-7.596</td>
<td>8.74E-12</td>
</tr>
<tr>
<td>NDC80</td>
<td>NDC80, kinetochore complex component</td>
<td>Up</td>
<td>9.22</td>
<td>3.36E-05</td>
</tr>
<tr>
<td>PLK1</td>
<td>Polo like kinase 1</td>
<td>Up</td>
<td>5.404</td>
<td>7.00E-04</td>
</tr>
<tr>
<td>POLE2</td>
<td>DNA polymerase epsilon 2, accessory subunit</td>
<td>Up</td>
<td>3.286</td>
<td>1.07E-03</td>
</tr>
<tr>
<td>PRC1</td>
<td>Protein regulator of cytokinesis 1</td>
<td>Up</td>
<td>2.942</td>
<td>9.31E-03</td>
</tr>
<tr>
<td>RFC3</td>
<td>Replication factor C subunit 3</td>
<td>Up</td>
<td>2.577</td>
<td>1.21E-02</td>
</tr>
<tr>
<td>SEL1L</td>
<td>SEL1L ERAD E3 ligase adaptor subunit</td>
<td>Down</td>
<td>-7.374</td>
<td>1.37E-07</td>
</tr>
<tr>
<td>SERPINH1</td>
<td>Serpin family H member 1</td>
<td>Up</td>
<td>4.907</td>
<td>6.57E-06</td>
</tr>
<tr>
<td>TMEM97</td>
<td>Transmembrane protein 97</td>
<td>Up</td>
<td>-25.777</td>
<td>4.37E-12</td>
</tr>
<tr>
<td>TOP2A</td>
<td>Topoisomerase (DNA) II alpha</td>
<td>Up</td>
<td>38.272</td>
<td>1.34E-07</td>
</tr>
<tr>
<td>TPX2</td>
<td>TPX2, microtubule nucleation factor</td>
<td>Up</td>
<td>31.538</td>
<td>3.55E-08</td>
</tr>
<tr>
<td>UBE2C</td>
<td>Ubiquitin conjugating enzyme E2 C</td>
<td>Up</td>
<td>34.639</td>
<td>5.00E-06</td>
</tr>
</tbody>
</table>

A Predicted regulation by RABL6A based on the RABL6A gene expression signature (microarray) in BON-1 cells with RABL6A expression versus knockdown (23)
B From RNA-Seq data in primary PNET specimens from 20 patients versus normal pancreas
C Select pathways in which the identified genes function, as identified by IPA analysis of the microarray and RNA-Seq datasets